CompanyPHIONasdaqKing Of Prussia, PA

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals is a clinical-stage company developing INTASYL, a siRNA technology that silences PD-1 to enhance immune cell killing of cancer cells.

Stories only

SEC EDGAR ClinicalTrials.gov phiopharma.com

8-KSep 28Latest SEC filing

Sep 28Latest story

September 2026

Phio Pharmaceuticals holds 2026 annual meeting, expands incentive plan

Sep 28PeoplePhio Pharmaceuticals Corp.

August 2026

Phio reports Q2 2026 results, sets Q3 FDA meeting on PH-762 path

Aug 6Quarterly updatePhio Pharmaceuticals Corp.

July 2026

Phio Pharmaceuticals adds dermatologist R. Todd Plott to board

Jul 21PeoplePhio Pharmaceuticals Corp.